Open an account

CorMedix

CRMD · NASDAQ

$7.57+$0.19 (+2.57%)TodayMarket closed ·
Prev close $7.38

About CRMD

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 191 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Employees
191
Headquarters
Berkeley Heights, New Jersey
Listed
Mar 25, 2010
Sector
Health Care
Industry
Pharmaceuticals
Website
cormedix.com

CRMD key statistics

Market cap
590.04M
Price-earnings ratio
3.60
Dividend yield
—
Average volume
1.04M
Volume
971.73K
Open price
$7.38
High today
$7.61
Low today
$7.38
52 Week high
$13.02
52 Week low
$6.13

CorMedix (CRMD) at a glance

As of Oct 20, 2026, CorMedix (CRMD) shares are priced at $7.57, giving the company a market cap of 590.04M and a price-to-earnings ratio of 3.60.

Today the stock has traded between $7.38 and $7.61. The current price is 2.6% above the day's low and 0.5% below its high.

Volume so far is 971.73K shares, in line with the average of 1.04M shares a day.

Over the past year CorMedix has ranged from $6.13 to $13.02, and now sits 21% of the way up that range.

CorMedix met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.29 per share against an estimate of $0.2428.

The average analyst price target is $15.64, 106.6% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 7 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $15.64
Low
$13.13
Now
$7.57
High
$19.95

CRMD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 45.8% on average.

  1. Q3 FY24: reported -$0.05 per share against an estimate of -$0.1048
  2. Q4 FY24: reported $0.22 per share against an estimate of $0.1428
  3. Q1 FY25: reported $0.30 per share against an estimate of $0.2652
  4. Q2 FY25: reported $0.28 per share against an estimate of $0.1763
  5. Q3 FY25: reported $1.26 per share against an estimate of $0.6581
  6. Q4 FY25: reported $0.16 per share against an estimate of $0.8325
  7. Q1 FY26: reported $0.49 per share against an estimate of $0.372
  8. Q2 FY26: reported $0.29 per share against an estimate of $0.2428

CRMD news

  • Press releasePRNewswire

    Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

  • Press releaseGlobe Newswire

    Today's Stocks in the News

  • Vandana Singh

    CorMedix Stock Jumps on Strong DefenCath Sales

  • Avi Kapoor

    Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

  • Vandana Singh

    CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Vandana Singh

    CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study

  • Cormedix Earnings Preview

Similar companies

Companies in the same industry as CorMedix

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.